AKT抑制剂capivasertib逆转EVI1驱动的急性髓系白血病维奈克拉耐药
该研究探讨EVI1高表达急性髓系白血病(AML)对维奈克拉耐药的机制。研究发现EVI1通过激活PI3K/AKT通路增加MCL-1在T163位点磷酸化,稳定MCL-1蛋白,从而介导耐药。维奈克拉联合AKT抑制剂capivasertib可恢复高EVI1表达的细胞系及患者原代AML样本对维奈克拉的敏感性。
要点
- EVI1高表达AML患者化疗或维奈克拉方案完全缓解率显著降低。
- EVI1通过PI3K/AKT通路增加MCL-1 T163磷酸化,稳定MCL-1蛋白。
- 维奈克拉联合capivasertib可恢复高EVI1表达AML的敏感性。
核心结论
- EVI1通过PI3K/AKT驱动的MCL-1稳定介导维奈克拉耐药,联合AKT抑制剂capivasertib可克服该耐药。
研究设计与样本
- 研究将AML患者按转录水平分为EVI1高组和EVI1低组,并在体外细胞系及患者原代AML样本中验证机制与联合用药效果。
主要发现
- EVI1高表达亚组临床结局显著更差,化疗或维奈克拉方案后完全缓解率降低。
- EVI1高表达通过激活PI3K/AKT通路增加MCL-1 T163磷酸化,减弱泛素-蛋白酶体降解从而稳定MCL-1。
- 维奈克拉联合capivasertib在高EVI1表达的细胞系和患者原代AML样本中有效恢复敏感性。
临床怎么用
- 对EVI1高表达AML患者,可考虑维奈克拉联合AKT抑制剂capivasertib以克服耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukaemia (AML) with MDS1 and EVI1 complex locus (MECOM) rearrangement is recognized by the World Health Organization as a distinct entity characterized by poor prognosis and aggressive disease progression. This rearrangement evokes aberrant ecotropic viral integration site 1 (EVI1) overexpression, which enhances leukaemic stem cell self-renewal and drives chemoresistance. However, the mechanisms by which EVI1 contributes to venetoclax resistance remain unclear. In this study, patients with AML were stratified into the EVI1-high and EVI1-low groups based on transcript levels. The EVI1-high subgroup exhibited significantly inferior clinical outcomes and reduced complete remission rates following chemotherapy or venetoclax-based regimens. Meanwhile, we demonstrated that elevated EVI1 expression confers resistance to venetoclax by stabilizing myeloid cell leukaemia 1 (MCL-1) through activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signalling pathway in vitro. Mechanistically, elevated EVI1 levels were associated with increased phosphorylation of MCL-1 at threonine 163 (T163pMCL-1), thereby stabilizing MCL-1 by attenuating its ubiquitin-proteasome-mediated degradation. Importantly, cotreatment with venetoclax and the clinically available AKT inhibitor capivasertib effectively restored sensitivity in both cell lines and patient-derived primary AML samples with high EVI1 expression. Overall, our findings reveal a novel molecular mechanism underlying EVI1-mediated venetoclax resistance through PI3K/AKT-driven MCL-1 stabilization and suggest a combination strategy involving AKT inhibition as a promising approach for overcoming therapeutic resistance in this high-risk AML subset.
引用
- Zhou J, Kui X, Huang D, et al. AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia. Br J Haematol. 2026. PMID: 42241446. doi:10.1111/bjh.70530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。